Zyvox Indications/Uses

Treatment of the following infections caused by susceptible strains of the designated microorganisms (see Precautions and Dosage & Administration): Treatment of MRSA and vancomycin-resistant enterococcus (VRE) of the following infections caused by gram-positive bacteria: Nosocomial pneumonia; complicated skin and soft tissue infections including diabetic foot infections without concomitant osteomyelitis caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes or Streptococcus agalacticiae. Zyvox has not been studied in the treatment of decubitus ulcers. Combination therapy may be clinically indicated if the documented or presumptive pathogens include gram-negative organisms.
Linezolid should only be initiated in a hospital environment and after consultation with a relevant specialist.
Linezolid is active against gram-positive bacteria only. Linezolid has no clinical activity against gram-negative pathogens. Specific gram-negative therapy is required if concomitant gram-negative pathogens is documented or suspected.
Consideration should be given to the official guidance on the appropriate use of antibacterial agents.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Zyvox and other antibacterial drugs, Zyvox should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.